计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
ETP-46321 is a potent and orally bioavailable PI3Kα and PI3Kδ inhibitor with K iapp s of 2.3 and 14.2 nM, respectively.
In Vitro
ETP-46321 is selected to be screened against other PI3K isoforms. ETP-46321 is more potent against isoform α (K iapp =2.3 nM). ETP-4632, has been profiled and shown to be a potent PI3K α and δ inhibitor, highly selective versus mTOR and 288 representative kinases. ETP-46321 is also tested against three of the p110α mutant enzymes detected in human cancers (E542K, E545K and H1047R), being equipotent against these mutants when compared to the wild type protein (K iapp =2.33, 1.77 and 1.89 nM for PI3Kα-H1047R, PI3Kα-E545K and PI3Kα-E542K, respectively). ETP-46321 inhibits the phosphorilation of AKT in U2OS cell line with an IC 50 of 8.3 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ETP-46321, is selected for in vivo studies based on its appealing pharmacokinetic profile in BALB-C mice, low in vivo Clearance (0.6 L/h/Kg) and good oral bioavailability (90%). ETP-46321 demonstrates a good pharmacokinetic profile in mice and is selected for preliminary in vivo evaluation in a lung tumor mouse model driven by a K-RasG12V oncogenic mutation, showing significant tumor growth inhibition, and reduction of the tumor metabolic activity as measured by positron emission tomography (PET) techniques . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:p110α 2.3 nM (Ki) PI3Kα-E545K 1.77 nM (Ki) PI3Kα-E542K 1.89 nM (Ki) PI3Kα-H1047R 2.33 nM (Ki) p110δ 14.2 nM (Ki) p110β 170 nM (Ki) p110γ 179 nM (Ki)